论文部分内容阅读
目的：探索阿司匹林（ASA）抗血小板治疗剂量的个体化，研究ASA剂量与血小板抑制作用之间的关系；方法：采用不同ASA剂量抑制血小板聚集功能（PAGT）的相关研究；结果：①ASA对血小板抑制作用在个体间存在明显差异；②体外ASA抑制敏感性与口服ASA50mg／d后的PAGT呈正相关（P＝0．043，列联系数＝0．254）；③冠心病组PAGT、T／K原始值高于其他二组；④三种剂量（50mg／d，25mg／d，12．5mg／d），ASA对血小板均有抑制作用，随剂量增大而增大；⑤本研究设定剂量范围的ASA对血小板聚集抑制作用未见性别差异。结论：体外ASA抑制血小板聚集试验可作为患者服用ASA剂量的一项参考指标。为尽量减少ASA副作用又达到抑制血小板功能最好选用起始负荷量及维持量。
To study the relationship between ASA dosage and platelet inhibitory effect.Methods: To study the relationship between ASA dosage and platelet aggregation inhibitory effect (PAGT) .Results: ① The effect of ASA on platelet inhibition (P = 0.043, the coefficient of association = 0.254); ③ The PAGT, T / K original in coronary heart disease group were significantly higher than that in the control group Higher than the other two groups; ④ The three doses (50mg / d, 25mg / d, 12.5mg / d), ASA inhibition of platelets, with the increase of dose; ⑤ This study set the dose range Of ASA on platelet aggregation inhibition no gender differences. CONCLUSIONS: In vitro ASA inhibition of platelet aggregation can be used as a reference for patients taking ASA doses. In order to minimize ASA side effects and achieve the best inhibition of platelet function starting load and maintenance volume.